Suppr超能文献

中间型地中海贫血:再探讨

Thalassemia intermedia: revisited.

作者信息

Taher Ali, Isma'eel Hussain, Cappellini Maria D

机构信息

Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon.

出版信息

Blood Cells Mol Dis. 2006 Jul-Aug;37(1):12-20. doi: 10.1016/j.bcmd.2006.04.005. Epub 2006 Jun 5.

Abstract

Thalassemia intermedia encompasses a wide clinical spectrum of beta-thalassemia phenotypes. Some thalassemia intermedia patients are asymptomatic until adult life, whereas others are symptomatic from as young as 2 years of age. A number of clinical complications commonly associated with thalassemia intermedia are rarely seen in thalassemia major, including extramedullary hematopoiesis, leg ulcers, gallstones and thrombophilia. Prevention of these complications, possibly with blood transfusion therapy, is ideal since they may be difficult to manage. Currently, many patients with thalassemia intermedia receive only occasional or no transfusions, since they are able to maintain hemoglobin levels between 7-9 g/dl; the risk of iron overload, necessitating adequate chelation therapy, is also a contributing factor. At present, there are no clear guidelines for initiating and maintaining transfusions in thalassemia intermedia for the prevention or treatment of complications. Here, we review the major clinical complications in thalassemia intermedia and suggest some therapeutic strategies based on retrospective clinical observations.

摘要

中间型地中海贫血涵盖了广泛的β地中海贫血表型临床谱。一些中间型地中海贫血患者直到成年期都没有症状,而另一些患者从2岁起就出现症状。许多与中间型地中海贫血常见相关的临床并发症在重型地中海贫血中很少见,包括髓外造血、腿部溃疡、胆结石和血栓形成倾向。由于这些并发症可能难以处理,理想的做法是通过输血治疗来预防。目前,许多中间型地中海贫血患者仅偶尔接受输血或不接受输血,因为他们能够将血红蛋白水平维持在7-9g/dl之间;铁过载的风险(需要进行充分的螯合治疗)也是一个促成因素。目前,对于中间型地中海贫血患者开始和维持输血以预防或治疗并发症,尚无明确的指南。在此,我们回顾中间型地中海贫血的主要临床并发症,并根据回顾性临床观察提出一些治疗策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验